3 results
Approved WMOCompleted
Primary: Longterm safety and tolerability.Secondary: Time to 1st flare, number and severity of flares, efficiacy in treating flares, effect on inflammatory markers, immunogenicity, PK.
Approved WMORecruiting
Primary objective:To assess the long term safety and tolerability of GIVINOSTAT in patients with DMD following core protocols program and with naïve GIVINOSTAT DMD subjects , i.e. subjects screened in study DSC/14/2357/48 who met:- all the inclusion…
Approved WMORecruiting
To assess the effect of BLU-5937 vs placebo on 24-hour cough frequencyin adults with RCC (including unexplained chronic cough) and Baseline24-hourcough frequency >=8 coughs/h at Week 12.To determine the safety of BLU-5937 vs placebo in adults…